Please select the option that best describes you:
Topics:
Genitourinary Cancers • Prostate Cancer • Bladder Cancer • Medical Oncology • Renal Cell Carcinoma • ESMO 2024
What are your top takeaways in GU Cancers from ESMO 2024?
Answer from: Medical Oncologist at Academic Institution
1. Tivozanib–nivolumab vs tivozanib monotherapy in patients with renal cell carcinoma (RCC) following 1 or 2 prior therapies including an immune checkpoint inhibitor (ICI): Results of the phase III TiNivo-2 study. This trial confirmed (along with CONTACT-03: cabozantinib +/- atezolizumab...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
NIAGARA trial in MIBC. First immunotherapy to show improved survival in the neoadjuvant setting in bladder/urothelial carcinoma. Powles et al. present LBA5, A Randomised Phase 3 Trial of Neoadjuvant Durvalumab Plus Chemotherapy Followed by Radical Cystectomy and Adjuvant Durvalumab in Muscle-invas...
Answer from: Medical Oncologist at Academic Institution
NIAGARA - NIAGARA phase 3 trial is practice changing showing significant EFS & OS benefit with the addition of durvalumab to 4 cycles of standard Gem/Cis neoadjuvant chemotherapy with the addition of up to 8 monthly adjuvant doses of durvalumab (peri-operative strategy). The addition to durval...
Answer from: Medical Oncologist at Community Practice
My top 3 abstracts were:
PEACE-3
NIAGARA
AMBASSADOR
All practice-changing